{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:46:23Z","timestamp":1772520383605,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Extended-release (ER) monthly injectable buprenorphine offers an alternative to daily sublingual (SL) dosing for treatment of opioid use disorder (OUD) that may be attractive to several patient populations, including those with barriers to adherence and the frequent follow-up that are necessary for traditional SL buprenorphine. Despite the potential benefits of ER-buprenorphine, there are significant barriers to healthcare provider adoption that may prevent utilization in the populations that would benefit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Our health system began providing clinic-administered ER-buprenorphine as treatment for OUD in May 2018 at a single clinic. Expansion was limited due to difficulties with delayed and inaccurate medication delivery and heavy administrative burden. To facilitate uptake of ER-buprenorphine for patients who could benefit, our integrated health-system specialty pharmacy (HSSP) assumed responsibility for medication distribution and administrative management beginning in October 2019. The HSSP provided accurate medication delivery, alleviated administrative burdens of benefits investigation and Risk Evaluation and Mitigation Strategy compliance, and decreased medication wastage by implementing a medication return process. Subsequently, ER-buprenorphine services were expanded to 4 additional sites, allowing 244 more patients to receive treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>HSSP support can provide significant benefit to patients and the health system through coordinating ER-buprenorphine dispensing and delivery.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac269","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T19:34:16Z","timestamp":1663961656000},"page":"e59-e66","source":"Crossref","is-referenced-by-count":5,"title":["Utility of an integrated health system specialty pharmacy in provision of extended-release buprenorphine for patients with opioid use disorder"],"prefix":"10.1093","volume":"80","author":[{"given":"Rushabh","family":"Shah","sequence":"first","affiliation":[{"name":"Specialty Pharmacy and Infusion Services, UK HealthCare , Lexington, KY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"Specialty Pharmacy and Infusion Services, UK HealthCare , Lexington, KY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fanucchi","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Center for Drug and Alcohol Research, University of Kentucky College of Medicine , Lexington, KY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lofwall","sequence":"additional","affiliation":[{"name":"Departments of Behavioral Science and Psychiatry, Center for Drug and Alcohol Research, University of Kentucky College of Medicine , Lexington, KY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thom","family":"Platt","sequence":"additional","affiliation":[{"name":"Specialty Pharmacy and Infusion Services, UK HealthCare , Lexington, KY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Rhudy","sequence":"additional","affiliation":[{"name":"Specialty Pharmacy and Infusion Services, UK HealthCare , Lexington, KY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"issue":"6","key":"2022121509185645400_CIT0001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013-2019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022121509185645400_CIT0002","article-title":"National Center for Health Statistics, Centers","year":"2022"},{"issue":"1","key":"2022121509185645400_CIT0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2022121509185645400_CIT0004","doi-asserted-by":"crossref","first-page":"108382","DOI":"10.1016\/j.drugalcdep.2020.108382","article-title":"The cost of opioid use disorder and the value of aversion","volume":"217","author":"Murphy","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"10182","key":"2022121509185645400_CIT0005","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2022121509185645400_CIT0006","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1360-0443.2007.02090.x","article-title":"Exposure to opioid maintenance treatment reduces long-term mortality","volume":"103","author":"Gibson","year":"2008","journal-title":"Addiction"},{"issue":"10173","key":"2022121509185645400_CIT0007","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"2022121509185645400_CIT0008","author":"Sublocade"},{"issue":"5","key":"2022121509185645400_CIT0009","doi-asserted-by":"crossref","first-page":"e219041","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2022121509185645400_CIT0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jsat.2019.06.007","article-title":"Opioid users\u2019 willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder","volume":"104","author":"Tompkins","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"2022121509185645400_CIT0011","doi-asserted-by":"crossref","first-page":"108221","DOI":"10.1016\/j.jsat.2020.108221","article-title":"Depot buprenorphine during COVID-19 in Australia: opportunities and challenges","volume":"124","author":"Arunogiri","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"2022121509185645400_CIT0012","doi-asserted-by":"crossref","first-page":"107616","DOI":"10.1016\/j.drugalcdep.2019.107616","article-title":"Characteristics and current clinical practices of opioid treatment programs in the United States","volume":"205","author":"Jones","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"2022121509185645400_CIT0013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addbeh.2017.05.010","article-title":"Predictors of buprenorphine treatment success of opioid dependence in two Baltimore city grassroots recovery programs","volume":"73","author":"Damian","year":"2017","journal-title":"Addict Behav"},{"key":"2022121509185645400_CIT0014","article-title":"New HHS guidance for increasing number of buprenorphine clinicians who can treat OUD","author":"Silwal","journal-title":"The Hospitalist"},{"key":"2022121509185645400_CIT0015","doi-asserted-by":"crossref","first-page":"108215","DOI":"10.1016\/j.jsat.2020.108215","article-title":"Telehealth sustains patient engagement in OUD treatment during COVID-19","volume":"122","author":"Langabeer","year":"2021","journal-title":"J Subst Abuse Treat"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac269\/46395348\/zxac269.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/1\/e59\/47884572\/zxac269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/1\/e59\/47884572\/zxac269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T21:54:10Z","timestamp":1671141250000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/1\/e59\/6712604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,23]]},"published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac269","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,9,23]]}}}